Title:
From protocol to guideline: The strategic use of scientific publications in clinical diabetes research

Simple item page
dc.contributor.author Hardeman, Sjoerd en_US
dc.contributor.corporatename Technische Universiteit Eindhoven en_US
dc.date.accessioned 2012-02-10T20:06:28Z
dc.date.available 2012-02-10T20:06:28Z
dc.date.issued 2011-09-15
dc.description Atlanta Conference on Science and Innovation Policy 2011 en_US
dc.description.abstract Numerous scholars have expressed concerns over the growing role of commercial interests in the academic domain (e.g. Nelson 2004). Notwithstanding the economic importance of bringing scientific knowledge to the market place, the role of industry in conducting academic research has been associated with practices that undermine prevailing norms of scientific conduct such as data-withholding practices (Cohen and Walsh 2008) and the creation of impediments to follow-up research through patenting (Murray and Stern 2007). The clinical sciences are a prime example in this context, where large pharmaceutical firms play a key role in research and development. These firms fund an increasing part of medical research at universities and hospitals, while they also increasingly outsource the operational aspects of clinical trials to private partners instead of academic ones. At the same time, scientific legitimation of clinical research outcomes in publications and ultimately in clinical guidelines has become ever more important. With the rise of an evidence based medicine paradigm (Timmermans and Berg 2003) - which attempts to directly ground medical decisions in scientific evidence - publishing even seems to have become a sine qua non for clinical success. Hence, publications are increasingly perceived as strategic tools that need to be carefully constructed and mobilized to maximize success towards medical practice. This paper addresses the strategic use of scientific publications in clinical research, taking diabetes mellitus research as an example. We study the determinants of research becoming published in scientific journals (either with positive or negative results) and of publications subsequently becoming included in clinical guidelines (as either a positive or negative guidance). We are particularly interested in whether providing authorships in industry-funded research to central academic actors (i.e. key opinion leaders) first increases the likelihood of publication and second increases the likelihood of these publications to be included in a clinical practice guideline subsequently. en_US
dc.description.sponsorship NWO (The Netherlands Organization for Scientific Research) en_US
dc.identifier.uri http://hdl.handle.net/1853/42502
dc.publisher Georgia Institute of Technology en_US
dc.relation.ispartofseries ACSIP11. Early Career Posters en_US
dc.subject Role of industry in conducting academic research en_US
dc.subject Scientific publications in clinical research en_US
dc.subject Industry-funded research en_US
dc.subject Clinical practice guidelines en_US
dc.subject Central academic actors as authors en_US
dc.title From protocol to guideline: The strategic use of scientific publications in clinical diabetes research en_US
dc.type Text
dc.type.genre Proceedings
dspace.entity.type Publication
local.contributor.corporatename Ivan Allen College of Liberal Arts
local.contributor.corporatename School of Public Policy
local.relation.ispartofseries Atlanta Conference on Science and Innovation Policy
relation.isOrgUnitOfPublication b1049ff1-5166-442c-9e14-ad804b064e38
relation.isOrgUnitOfPublication a3789037-aec2-41bb-9888-1a95104b7f8c
relation.isSeriesOfPublication 8e93dc09-10dd-4fdd-8c5a-77defb1f7f78
Files
Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
478-1578-1-PB.docx
Size:
19.6 KB
Format:
Microsoft Word
Description:
Extended Abstract
Download
Collections
Scholarly Events